Reduced regional cortical thickness rate of change in donepezil-Treated subjects with suspected prodromal Alzheimer's disease

Journal of Clinical Psychiatry

Volumn 77, Issue 12, 2016, Pages e1631-e1638

  Cavedo, Enrica ^b,c,d,e   Dubois, Bruno ^a,b,c   Colliot, Olivier ^b,c,f,g,h   Lista, Simone ^a,b,c   Croisile, Bernard ⁱ   Tisserand, Guy Louis ⁱ   Touchon, Jacques ^j   Bonafe, Alain ^j   Ousset, Pierre J ^k   Rouaud, Olivier ^l   Ricolfi, Frederic ^m   Vighetto, Alain ⁿ   Pasquier, Florence ⁿ   Galluzzi, Samantha ^e   Delmaire, Christine ^o   Ceccaldi, Mathieu ^p,q   Girard, Nadine ^a,p   Lehericy, Stephane ^b,c,d   Duveau, Francoise ^a   Chupin, Marie ^b,c,f,g,h   Sarazin, Marie ^r   Dormont, Didier ^b,c,f,g,h   Hampel, Harald ^a,b,c,g   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CATI Multicenter Neuroimaging Platform   (France)

^e IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^f INSERM   (France)

^g CNRS   (France)

^h INRIA ROCQUENCOURT   (France)

ⁱ HÔPITAL NEUROLOGIQUE   (France)

^j MONTPELLIER UNIVERSITY HOSPITAL   (France)

^k Toulouse University   (France)

^l HÔPITAL DU BOCAGE   (France)

^m UNIVERSITÉ LYON 1   (France)

ⁿ CHU Lille   (France)

^o UNIV LILLE   (France)

^p TIMONE HOSPITAL   (France)

^q Eisai SAS   (France)

^r UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; DONEPEZIL; PLACEBO; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ANTERIOR CINGULATE; APOE GENE; ARTICLE; BRAIN REGION; COHORT ANALYSIS; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DOUBLE BLIND PROCEDURE; FEMALE; HIPPOCAMPUS; HUMAN; INFERIOR FRONTAL GYRUS; INSULA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AMNESIA; BRAIN CORTEX; CLINICAL TRIAL; COGNITIVE DYSFUNCTION; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG EFFECTS; MULTICENTER STUDY; PRODROMAL SYMPTOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMNESIA; CEREBRAL CORTEX; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NOOTROPIC AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PIPERIDINES; PRODROMAL SYMPTOMS;

EID: 85007521355     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10413     Document Type: Article

References (43)

1. Johannsen P, Salmon E, Hampel H, et al; AWARE Study Group. Assessing therapeutic efficacy in a progressive disease: A study of donepezil in Alzheimers disease. CNS Drugs. 2006;20(4):311-325. doi:10.2165/023210-2062040-05
2. Crane PK, Doody RS. Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial. Neurology. 2009;73(18):1514-1515, author reply 1515-1516. doi:10.1212/WNL.0b013e3181bd6c25
3. Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial. Neurology. 2009;72(18):1555-1561. doi:10.1212/01.wnl.034650.95823.03
4. Doody RS, Ferris S, Salloway S, et al. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen. 2010;25(2):155-159. doi:10.17/1531750935234
5. Feldman H, Gauthier S, Hecker J, et al; Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimers disease. Neurology. 2001;57(4):613-620. doi:10.1212/WNL.57.4.613
6. Feldman H, Gauthier S, Hecker J, et al; Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimers disease and the effect on caregiver burden. J Am Geriatr Soc. 2003;51(6):737-744. doi:10.1046/j.1365-2389.203.51260.x
7. Feldman H, Gauthier S, Hecker J, et al; Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimers disease: A subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20(6):559-569. doi:10.102/gps.1325
8. Gauthier S, Feldman H, Hecker J, et al; Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimers disease. Int Psychogeriatr. 2002;14(4):389-404. doi:10.1017/S10416102020858X
9. Petersen RC, Thomas RG, Grundman M, et al; Alzheimers Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388. doi:10.1056/NEJMoa050151
10. Salloway S, Ferris S, Kluger A, et al; Donepezil 401 Study Group. Efficacy of donepezil in mild cognitive impairment: A randomized placebocontrolled trial. Neurology. 2004;63(4):651-657. doi:10.1212/01.WNL.013464.80320.92
11. Teipel SJ, Drzezga A, Bartenstein P, et al. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimers disease: A double-blind cross-over trial. Psychopharmacology (Berl). 2006;187(1):86-94. doi:10.107/s0213-06-0408-1
12. Jack CR Jr, Petersen RC, Grundman M, et al; Members of the Alzheimers Disease Cooperative Study (ADCS). Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008;29(9):1285-1295. doi:10.1016/j.neurobiolaging.207.03.04
13. Schuff N, Suhy J, Goldman R, et al. An MRI substudy of a donepezil clinical trial in mild cognitive impairment. Neurobiol Aging. 2011;32(12):2318.e31-2318.e41. doi:10.1016/j.neurobiolaging.2010.04.05
14. Dubois B, Chupin M, Hampel H, et al; Hippocampus Study Group. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimers disease. Alzheimers Dement. 2015;11(9):1041-1049. doi:10.1016/j.jalz.2014.10.03
15. Teipel SJ, Grothe M, Lista S, et al. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med Clin North Am. 2013;97(3):399-424. doi:10.1016/j.mcna.2012.12.013
16. Hampel H, Burger K, Teipel SJ, et al. Core candidate neurochemical and imaging biomarkers of Alzheimers disease. Alzheimers Dement. 2008;4(1):38-48. doi:10.1016/j.jalz.207.08.06
17. Teipel SJ, Meindl T, Grinberg L, et al. Novel MRI techniques in the assessment of dementia. Eur J Nucl Med Mol Imaging. 2008;35(suppl 1): S58-S69. doi:10.107/s0259-07-0703-z
18. Wagner M, Wolf S, Reischies FM, et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology. 2012;78(6):379-386. doi:10.1212/WNL.0b013e318245f47
19. Sarazin M, Chauvire V, Gerardin E, et al. The amnestic syndrome of hippocampal type in Alzheimers disease: An MRI study. J Alzheimers Dis. 2010;22(1):285-294.
20. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimers disease. Am J Psychiatry. 1984;141(11):1356-1364. doi:10.176/ajp.141.1.1356
21. Delis DC, Kramer JH, Kaplan E, et al. California Verbal Learning Test, Adult Version: Manual. San Antonio, TX: Psychological Corporation; 1987.
22. Tombaugh, TN (2004). Trail Making Test A and B: normative data stratified by age and education. Archives of Clinical Neuropsychology, 19(2), 203-214.
23. Benton AL. The Revised Visual Retention Test. New York, NY: The Psychological Corporation; 1974.
24. Bernal-Rusiel JL, Greve DN, Reuter M, et al; Alzheimers Disease Neuroimaging Initiative. Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage. 2013;66:249-260. doi:10.1016/j.neuroimage.2012.10.065
25. Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: A robust approach. Neuroimage. 2010;53(4):1181-1196. doi:10.1016/j.neuroimage.2010.07.020
26. Reuter M, Schmansky NJ, Rosas HD, et al. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage. 2012;61(4):1402-1418. doi:10.1016/j.neuroimage.2012.02.084
27. Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968-980. doi:10.1016/j.neuroimage.206.01.021
28. Templeton GF. A two-step approach for transforming continuous variables to normal: implications and recommendations for IS research. Commun Assoc Info Syst. 2011;28(4):41-58.
29. Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology. 2009;72(12):1048-1055. doi:10.1212/01.wnl.0340981.9764.2f
30. Dickerson BC, Wolk DA; Alzheimers Disease Neuroimaging Initiative. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology. 2012;78(2):84-90. doi:10.1212/WNL.0b013e31823efc6c
31. Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimers disease. Am J Psychiatry. 2003;160(11):2003-2011. doi:10.176/api.ajp.160.1.203
32. Schuff N, Woerner N, Boreta L, et al; Alzheimers Disease Neuroimaging Initiative. MRI of hippocampal volume loss in early Alzheimers disease in relation to ApoE genotype and biomarkers. Brain. 2009;132 (pt 4):1067-1077. doi:10.1093/brain/awp07
33. Lerch JP, Pruessner J, Zijdenbos AP, et al. Automated cortical thickness measurements from MRI can accurately separate Alzheimers patients from normal elderly controls. Neurobiol Aging. 2008;29(1):23-30. doi:10.1016/j.neurobiolaging.206.09.013
34. Toga AW, Thompson PM. Mapping brain asymmetry. Nat Rev Neurosci. 2003;4(1):37-48. doi:10.1038/nrn109
35. Svensson AL, Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells. Neuroreport. 1998;9(7):1519-1522. doi:10.1097/01756-1980510-050
36. Wolf BA, Wertkin AM, Jolly YC, et al. Muscarinic regulation of Alzheimers disease amyloid precursor protein secretion and amyloid betaprotein production in human neuronal NT2N cells. J Biol Chem. 1995;270(9):4916-4922. doi:10.1074/jbc.270.9.4916
37. Wallace W, Ahlers ST, Gotlib J, et al. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc Natl Acad Sci U S A. 1993;90(18):8712-8716. doi:10.1073/pnas.90.18.8712
38. Grothe MJ, Ewers M, Krause B, et al; Alzheimers Disease Neuroimaging Initiative. Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement. 2014;10(5 suppl): S344-S353. doi:10.1016/j.jalz.2013.09.01
39. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 1978;2(6150):1457-1459. doi:10.136/bmj.2.6150.1457
40. Beach TG, McGeer EG. Senile plaques, amyloid beta-protein, and acetylcholinesterase fibres: laminar distributions in Alzheimers disease striate cortex. Acta Neuropathol. 1992;83(3):292-299. doi:10.107/BF0296792
41. Arendt T, Bigl V, Tennstedt A, et al. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimers disease. Neuroscience. 1985;14(1):1-14. doi:10.1016/0306-452(85)90160-5
42. Kar S, Slowikowski SP, Westaway D, et al. Interactions between beta-Amyloid and central cholinergic neurons: implications for Alzheimers disease. J Psychiatry Neurosci. 2004;29(6):427-441.
43. Selden NR, Gitelman DR, Salamon-Murayama N, et al. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain. 1998;121(pt 12):2249-2257. doi:10.1093